USANA Health Sciences

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

USANA Health Sciences addresses challenges, eyes growth through cost management

USANA Health Sciences navigated a challenging operating environment by focusing on cost management, product demand trends, and growth strategies. Despite facing headwinds in China and Southeast Asia, the company remains resilient and poised for opportunities in new markets and acquisitions.

USANA Health Sciences reports solid Q1 results amid global challenges

USANA Health Sciences delivered strong Q1 results amidst global challenges, driven by robust demand for health products.
Strategic leadership transition and focus on cost management position the company for sustained growth and operational efficiency.
Opportunities in China market, new market launches, and enhanced customer engagement strategies offer avenues for future expansion.

USANA Health Sciences exceeds Q2 expectations, eyes India expansion

USANA Health Sciences delivered strong Q2 results with a focus on sustainable growth strategies and expansion into new markets. Challenges include tough year-over-year comparisons and cash flow impact from accrued liabilities.

USANA Health Sciences addresses challenges, eyes India expansion for growth

USANA Health Sciences navigated challenges in Q3 2023 with a focus on addressing operational hurdles and driving growth through strategic initiatives. The company's restructuring and expansion into India signal a commitment to long-term success and capitalizing on emerging opportunities.

USANA Health Sciences exceeds Q4 expectations, eyes global growth

USANA Health Sciences delivered strong performance in Q4 2023, driven by growth in Greater China and a solid financial position. While facing challenges such as currency fluctuations and market-specific issues, the company is well-positioned to capitalize on opportunities through strategic initiatives and market tailoring. By focusing on sustainable growth and innovation, USANA aims to further strengthen its market presence and drive profitability.

USANA Health Sciences reports mixed Q1 results, eyes growth strategies

USANA Health Sciences faced mixed results in Q1 2024, with Mainland China driving growth while other markets struggled. The company is addressing challenges through market-specific incentives and focusing on future strategies like product development and localization.

USANA Health Sciences adapts to market challenges with strategic focus

USANA Health Sciences navigated macroeconomic challenges by implementing strategic initiatives and restructuring its commercial team.
The company's focus on product innovation, market expansion into India, and leadership additions signal a commitment to sustainable success.
While facing challenges in market conditions, USANA aims to leverage opportunities like M&A activities and accelerated product development for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q4 2019 Results - Earnings Call Transcript

Usana Health Sciences Inc. USNA, +4.62% shares rallied in the extended session Tuesday after the nutritional supplements company reported quarterly results that topped Wall Street expectations and forecast a strong outlook.

Usana stock rallies more than 20% on earnings, outlook

Brinker International

Eagle Bancorp

Green Dot

Hawaiian Hlds

Rush Enterprises

Companies that are growing their earnings are often good investments because they can return a solid profit to investors.

6 Bargain Stocks Growing Earnings

Sales and earnings fell for the global cellular nutrition company in Q3, but it still managed to beat Wall Street expectations.

What's Behind USANA Health Sciences' Q3 Earnings Beat

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q3 2019 Results - Earnings Call Transcript

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q2 2019 Results - Earnings Call Transcript

The nutrition company reported mainly bad news with its Q2 earnings update.

What You'll Want to Know About USANA Health Sciences' Q2 Earnings

Broadcom

Electronic Arts

Find out what made these stocks miss today's rally.

Why Electronic Arts, USANA Health Sciences, and Broadcom Slumped Today

USANA Health Sciences (NYSE: USNA) shares are trading sharply lower after the company cut its FY2019 EPS and sales guidance below analyst estimates.

USANA Issues Concerning Guidance, Shares Slammed

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q1 2019 Results - Earnings Call Transcript

News for USANA Health Sciences Stock (USNA)